Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
News provided by
Share this article
Share this article
AUSTIN, Texas, April 1, 2021 /PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021.
Conference Details
Conference Date: Tuesday, April 6 and Thursday, April 8
Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea s president and chief executive officer and Michael C. Hanley, Aeglea s chief commercial officer
Conference Name: 20
Conference Date: Monday, April 12 through Thursday, April 15